No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Established in Tokyo, Japan, in 1893, Tsumura & Co. operates worldwide in the pharmaceutical sector. The company's core business involves the creation and international distribution of various medicinal products, with a particular focus on Kampo extract intermediates and granular Kampo preparations. Its operations are comprehensive, encompassing the full supply chain: from the careful acquisition, selection, processing, and warehousing of raw herbal materials and crude drug components for decoctions, to the manufacturing of powdered Kampo extracts and traditional Chinese medicines. Additionally, Tsumura & Co. is engaged in the sale of both pharmaceutical goods and food products.
www.tsumura.co.jpNo one on the platform currently holds 4540.T.
No tracked institution reports a position in 4540.T as of their last filing.
No one on the platform has traded 4540.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 6.8% | 7.3% | 7.2% | — | — | — |
| Rev. Growth % | 6.4% | 8.0% | ||||
| Profit Margin % | 14.6% | 14.0% | 12.8% | |||
| Free Cash Flow Margin % | -4.2% | 0.7% | 3.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $214.6B | +10.0% | $345.50 | $294.37–$390.24 | — | 4 |
| 2028 | $228.1B | +6.3% | $356.65 | $250.89–$433.36 | — | 4 |
| 2029 | $238.3B | +4.4% | $366.69 | $244.40–$428.28 | — | 4 |
| 2030 | $248.4B | +4.3% | $338.85 | $329.74–$348.06 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-13 | $93.28 | $66.68 | -28.5% |
| 2026-02-06 | $90.93 | $142.95 | +57.2% |
| 2025-11-10 | $90.93 | $108.49 | +19.3% |
| 2025-08-05 | $90.93 | $58.16 | -36.0% |
| 2025-05-12 | $124.55 | $77.27 | -38.0% |
| 2025-02-06 | $93.54 | $119.37 | +27.6% |
| 2024-11-07 | $93.54 | $83.26 | -11.0% |
| +0.00% |
| $425.2B |
| — |
| 4547.TKissei Pharmaceutical Co., Ltd. | $4025.00 | +0.12% | $166.8B | — |
| 4553.TTowa Pharmaceutical Co., Ltd. | $3640.00 | +2.54% | $179.2B | — |
Source: Financial Modeling Prep · peers by sector/industry